Trial reportBMC cancer2026
Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundModerately hypofractionated radiotherapy is increasingly replacing conventional schedules (2 Gy/fraction) in adjuvant breast cancer treatment. Tumor-infiltrating lymphocytes (TILs) have emerged as a prognostic biomarker, particularly in aggressive subtypes, but their role in node-negative patients and their relation to radiotherapy fractionation remain unclear. MATERIALS AND
methodsImmune infiltration in primary tumors was examined in the randomized Danish Breast Cancer Group HYPO trial, including 1329 node-negative breast cancer patients treated with breast-conserving surgery and randomized to standard fractionated (50 Gy/25 fractions) versus hypofractionated (40 Gy/15 fractions) radiotherapy. A case-cohort design included 349/1329 patients for histopathological analyses of TILs and immune cell subsets (CD8, CD4, FOXP3, CD68, CD11c). Associations with the primary endpoint, overall mortality (OM), were evaluated using multivariable flexible parametric survival models. Predictive effects of immune markers on fractionation were assessed through interaction tests.
resultsMedian follow-up was 7.9 years. High TILs (cut-off ≥ 30%) were observed in 18% of tumors and showed a trend toward improved outcomes, most pronounced in patients with estrogen receptor (ER)-negative tumors (hazard ratio (HR) 0.43, 95% CI (0.09–2.03)). For ER-negative tumors, high CD8 + T-cell infiltration corresponded to an estimated absolute reduction in OM-risk of 43% compared with low CD8 + T-cell infiltration (HR 0.06 (0.01–0.47), test for interaction p = 0.13). In contrast, no consistent prognostic effect was observed in ER-positive disease. No predictive interaction was identified between immune markers and fractionation.
conclusionImmune infiltration showed trends consistent with a prognostic association in node-negative breast cancer, with the strongest association in ER-negative tumors, in line with findings in node-positive cohorts. No predictive value of immune markers for fractionation was observed. These exploratory findings suggest that immune composition may hold prognostic information across risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.